Vertex stock forecast: scenarios through 2029
Vertex's weighted outcome is $497.80 in October 2027 and $555.05 in October 2029, with 25% bear, 55% base and 20% bull probabilities. It hinges on CF durability, new-launch conversion and Crinetics execution.
Where could Vertex's shares be by 2029?
The forecast puts the shares at $497.80 in October 2027, $522.94 in October 2028 and $555.05 in October 2029, with dividends included. Those outcomes represent roughly no return, 5% and 11% from today’s $498.50.
By October 2029, the bear case gives $307.19 and the bull case gives $889.26. The full range is therefore $307.19 to $889.26. The probabilities are 25% bear, 55% base and 20% bull.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 375.40 (-25 %) | 341.95 (-31 %) | 307.19 (-38 %) |
| Base | 55 % | 512.39 (+3 %) | 525.97 (+6 %) | 546.18 (+10 %) |
| Bull | 20 % | 610.67 (+23 %) | 740.84 (+49 %) | 889.26 (+78 %) |
| Weighted | 100 % | 497.80 (-0 %) | 522.94 (+5 %) | 555.05 (+11 %) |
What has to go right, and what could go wrong for Vertex?
By October 2029, CF growth slows as the treated population matures and ALYFTREK switching mostly shifts sales between products. JOURNAVX prescriptions convert slowly into paid use, CASGEVY infusions remain limited by the treatment journey, and Crinetics integration adds debt and execution pressure. The case leads to $375.40 in October 2027 and $307.19 in October 2029. Its probability is 25% because CF remains a durable cash engine, but the newer growth drivers are not yet proven.
New CF starts offset saturation, JOURNAVX becomes routine paid therapy, CASGEVY treatment centers convert more referrals, and Crinetics integrates smoothly. Earnings growth, buybacks and a higher multiple then lead to $610.67 in October 2027 and $889.26 in October 2029. Its probability is 20% because each step carries commercial, clinical or financing risk.
How much cash does Vertex really make?
Net income was $3,953.2 million in 2025. Cash from operations was $3,631.4 million, and after $437.6 million of capital spending, free cash flow was $3,193.8 million. That represented 26.6% of revenue, down from 44.0% in 2022. The business grew, but free cash flow remained below 2023’s $3,278.9 million.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 3,631.4 | -492.6 | 3,537.3 | 4,129.9 | 2,643.5 |
| − Capital spending | 437.6 | 485.4 | 258.4 | 204.7 | 235.0 |
| = Free cash flow | 3,193.8 | -978.0 | 3,278.9 | 3,925.2 | 2,408.5 |
| − Stock pay | 685.9 | 698.5 | 581.2 | 491.3 | 441.4 |
| = Real free cash flow | 2,507.9 | -1,676.5 | 2,697.7 | 3,433.9 | 1,967.1 |
| Real free cash flow, % of revenue | 20.9% | -15.2% | 27.3% | 38.5% | 26.0% |
What this means. Stock pay is subtracted even though no cash leaves today because employees receive shares, which reduces what each existing shareholder owns.
What does an investor pay for Vertex today?
| Today (Oct 14, 2026) | |
|---|---|
| Share price | 498.50 |
| Market value (calculated) | 126,350.3 |
| P/E, last 12 months (calculated) | 29.0x |
| P/E, next 12 months (calculated) | 23.7x |
| Free cash flow yield (calculated) | 2.5% |
| Real free cash flow yield (calculated) | 2.0% |
What this means. The next twelve months price-to-earnings ratio uses analysts' guesses about future profit, so it may be wrong.